Captopril restores endothelium-dependent relaxation induced by advanced oxidation protein products in rat aorta

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 6, 2005, Pages 803-809

  Chen, Shuangxiu ^a   Liu, Liying ^a   Sun, Xueying ^a   Liu, Yuhui ^a   Song, Tao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Advanced oxidation protein products; Captopril; Endothelium; L arginine; Nitric oxide; Superoxide dismutase

Indexed keywords

ACETYLCHOLINE; ADVANCED OXIDATION PROTEIN PRODUCT; ARGININE; BOVINE SERUM ALBUMIN; CAPTOPRIL; DEXTRO ARGININE; ENALAPRILAT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; OXYGEN RADICAL; PROTEIN DERIVATIVE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; PLASMA PROTEIN;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION; ANIMAL; AORTA; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; AORTA; BLOOD PROTEINS; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; MALE; NITRIC OXIDE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; VASODILATION;

EID: 33644683280     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000188162.64642.c7     Document Type: Article

References (37)

1. Capeille're-Blandin C, Vale'rie G, Descamps-Latsch B, et al. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta. 2004;1689:91-102.
2. Witko-Sarsat V, Friedlander M, Capeille're-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-1313.
3. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis. 2005;45:39-47.
4. Kalousova M, Krha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002;51:597-604.
5. Hideaki K, Junichi T, Ken O, et al. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis. 2002;162:221-225.
6. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem. 2000;267:4495-4503.
7. Brasen JH, Hakkinen T, Malle E, et al. Patterns of oxidized epitopes, but not NF-kappa B expression, change during atherogenesis in WHHL rabbits. Atherosclerosis. 2003;166:13-21.
8. Malle E, Woenckhaus C, Waeg G, et al. Immunological evidence for hypochlorite-modified proteins in human kidney. Am J Pathol. 1997;150:603-615.
9. Grone HJ, Grone EF, Malle E. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab Invest. 2002;82:5-14.
10. Yuan F, Liu SX, Tian JW. Advanced oxidation protein products induce reactive oxygen species production in endothelial cells. J First Mil Med Univ. 2004;24:1350-1352.
11. Nele T, Deppisch R, Beck W, et al. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant. 1999;14:1968-1975.
12. Fu S, Wang H, Davies M, et al. Reactions of hypochlorous acid with tyrosine and peptidyl-tyrosyl residues give dichlorinated and aldehydic products in addition to 3-chlorotyrosine. J Biol Chem. 2000;275:10851-10858.
13. Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int. 2001;60:358-363.
14. Witko-Sarsat V, Friedlander M, Nguyen AT, et al. Advanced oxidation protein products as a novel inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524-2532.
15. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15:S65-S72.
16. Yun-Feng F, Yan Y, Si-Hai F. Captopril restores endothelium-dependent relaxation of rat aortic rings after exposure to homocysteine. J Cardiovasc Pharmacol. 2003;42:566-572.
17. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima media thickness in end-stage renal disease. Circulation. 2002;106:2212-2217.
18. Martin-Gallan P, Carrascosa A, Gussinye M, et al. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med. 2003;34:1563-1574.
19. Buonocore G, Perrone S, Longini M, et al. Oxidative stress in preterm neonates at birth and on the seventh day of life. Pediatr Res. 2002;52:46-49.
20. Alderman CJ, Shah S, Foreman JC, et al. The role of advanced oxidation protein products in regulation of dendritic cell function. Free Radic Biol Med. 2002;32:377-385.
21. Zhang ZH, Liu SX, Hou FF, et al. Advanced oxidation protein products-induced tumor necrosis factor alpha secretion in monocytes via reactive oxygen species generation. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:493-497.
22. Webb A, Bond R, McLean P, et al. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA. 2004;101:13683-13688.
23. Morena M, Cristol JP, Bosc JY, et al. Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant. 2002;17:422-427.
24. Wu CC, Chen JS, Wu WM, et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant. 2005;20:1134-1139.
25. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004;148:172-178.
26. Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002;39:634-638.
27. Goldschmidt JE, Tallarida RJ. Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: effect of sulthydryl groups on endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1991;257:1136-1145.
28. Yasutaka O, Kiyotaka K, Seigo S, et al. Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract - role of free radicals and attenuation by captopril. Atherosclerosis. 1997;131:195-202.
29. Torok J, Babal P, Matuskova J, et al. Impaired endothelial function of thoracic aorta in hereditary hypertriglyceridemic rats. Ann N Y Acad Sci. 2002;967:469-475.
30. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vaso-motor dysfunction in patients with coronary artery disease: the TREND (Trial on reversing endothelial dysfunction study). Circulation. 1996;94:258-265.
31. Goldschmidt JE, Tallarida RJ. Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: effect of sulfhydryl groups on endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1991;257:1136-1145.
32. Chopra M, Beswick H, Clapperton M, et al. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol. 1992;19:330-340.
33. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol. 2003;482:95-99.
34. de Nigris F, D'Armiento FP, Somma P, et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol. 2001;81:107-115.
35. Anning PB, Grocott-Mason RM, Lewis MJ. Effects of sulphydryl- and non-sulphydryl-containing ACE inhibitors on left ventricular relaxation in the isolated guinea pig heart. Endothelium. 1997;5:265-275.
36. Bode-Böger SM, Böger RH, Kienke S, et al. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun. 1996;219:598-603.
37. Grafe M, Bossaller C, Graf K, et al. Effect of angiotensin-converting enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am J Physiol. 1993;264:H1493-H1497.